---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-015770"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-09-15T23:59:59+00:00"
generated_at: "2026-06-10T15:55:46.502649+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CHMP issues negative opinion on Translarna full authorization; PTC to seek re-examination

## Summary
- CHMP gave negative opinion on converting Translarna's conditional MA to full MA for nmDMD.
- Negative opinion also applies to renewal of existing conditional authorization.
- PTC will submit re-examination request; expected CHMP opinion in Jan 2024, EC ratification within 67 days.
- Translarna stays on market for nmDMD patients during re-examination process.
- PTC cites favorable safety profile & efficacy data from 3 placebo-controlled trials and STRIDE registry.

## SEC filing metadata
- accession: 0001558370-23-015770
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-09-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837023015770/0001558370-23-015770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837023015770/tmb-20230915x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-015770
- JSON: https://secwatch.observer/filing/0001558370-23-015770.json
- Plain text: https://secwatch.observer/filing/0001558370-23-015770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.